Publication Bias and Outcome Reporting Bias: Agomelatine as a Case Example

A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression

(2011) Robert H. Howland   DRUG SAFETY

What You See Depends on Where You’re Looking and How You Look at It: Publication Bias and Outcome Reporting Bias

(2011) Robert H. Howland   JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES

Novel melatonin-based therapies: potential advances in the treatment of major depression

(2011) Ian B Hickie et al.   LANCET

Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder

(2010) Siegfried Kasper et al.   JOURNAL OF CLINICAL PSYCHIATRY

Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults

(2010) Robert Howland   Neuropsychiatric Disease and Treatment

A Double-Blind Comparison of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between Agomelatine and Venlafaxine XR

(2008) Sidney H. Kennedy et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale

(2008) AL Montejo et al.   JOURNAL OF PSYCHOPHARMACOLOGY